Please assess the completion status of the following clinical trial:

Trial Title: Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \>=17 years with diagnosis of CD for at least 3 months defined by histology or radiology~* ileocolonic non-penetrating disease~* Moderate active CD with CDAI 250-450~* CRP level over normal range~* Stable CD therapy with a total steroid dose not exceeding 10mg prednisolone or equivalent for 4 weeks~Exclusion Criteria:~* Infection with enteric pathogen~* Usage of probiotics, antibiotics, or prebiotics within the last month~* Change in dose of oral steroids or 5-ASA within the last 4 weeks or AZA or MTX in the last 3 months~* Dose of steroids exceeds 10 mg prednisolone per day or equivalent~* Infusion of IFX or any alternative biological therapy within the last 3 months~* Use of rectal 5-ASA or steroids within the last 2 weeks.~* Imminent need for surgery or presence of severe disease (CDAI \>450)~* Pregnancy or lactation~* Short bowel syndrome or subtotal/total colectomy~* Pure anal disease and previous proctocolectomy~* Significant hepatic, renal, endocrine, respiratory, neurological or cardiovascular disease as determined by the principal investigator~* History of cancer with a disease-free state of less than two years~* Patients with penetrating disease or small bowel lesion only.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- pectin (Type: EXPERIMENTAL): Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
- control (Type: PLACEBO_COMPARATOR): Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).